| The complete genome sequence of Clostridium aceticum: a missing link between Rnf-and cytochrome-containing autotrophic acetogens A Poehlein, M Cebulla, MM Ilg, FR Bengelsdorf, B Schiel-Bengelsdorf, ... MBio 6 (5), 10.1128/mbio. 01168-15, 2015 | 85 | 2015 |
| A dynamic role of TBX3 in the pluripotency circuitry R Russell, M Ilg, Q Lin, G Wu, A Lechel, W Bergmann, T Eiseler, L Linta, ... Stem cell reports 5 (6), 1155-1170, 2015 | 67 | 2015 |
| Antifibrotic synergy between phosphodiesterase type 5 inhibitors and selective oestrogen receptor modulators in Peyronie's disease models MM Ilg, M Mateus, WJ Stebbeds, U Milenkovic, N Christopher, A Muneer, ... European urology 75 (2), 329-340, 2019 | 52 | 2019 |
| Pathophysiology and future therapeutic perspectives for resolving fibrosis in Peyronie’s disease U Milenkovic, MM Ilg, S Cellek, M Albersen Sexual Medicine Reviews 7 (4), 679-689, 2019 | 36 | 2019 |
| Simvastatin and the Rho‐kinase inhibitor Y‐27632 prevent myofibroblast transformation in Peyronie's disease‐derived fibroblasts via inhibition of YAP/TAZ nuclear translocation U Milenkovic, MM Ilg, C Zuccato, Y Ramazani, D De Ridder, M Albersen BJU international 123 (4), 703-715, 2019 | 29 | 2019 |
| Understanding the role of adenosine receptors in the myofibroblast transformation in Peyronie’s disease M Mateus, MM Ilg, WJ Stebbeds, N Christopher, A Muneer, DJ Ralph, ... The Journal of Sexual Medicine 15 (7), 947-957, 2018 | 26 | 2018 |
| Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease MM Ilg, SJ Stafford, M Mateus, SA Bustin, MJ Carpenter, A Muneer, ... The Journal of Sexual Medicine 17 (10), 1848-1864, 2020 | 24 | 2020 |
| European Society for Sexual Medicine consensus statement on the use of the cavernous nerve injury rodent model to study postradical prostatectomy erectile dysfunction E Weyne, MM Ilg, OO Cakir, A Muneer, DB Roussel, M Albersen, J Angulo, ... Sexual Medicine 8 (3), 327-337, 2020 | 15 | 2020 |
| Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie’s disease MM Ilg, AR Lapthorn, DJ Ralph, S Cellek PLoS One 17 (12), e0277646, 2022 | 7 | 2022 |
| Unwinding fibrosis in peyronie's disease MM Ilg, S Cellek The Journal of Sexual Medicine 17 (5), 838-840, 2020 | 7 | 2020 |
| Phenotypic screening identifies hydroxypyridone anti-fungals as novel medicines for the prevention of hypertrophic scars AR Lapthorn, MM Ilg, JV Sullivan, P Dziewulski, S Cellek European Journal of Pharmacology 937, 175374, 2022 | 6 | 2022 |
| Statins synergize with phosphodiesterase type 5 inhibitors but not with selective estrogen receptor modulators to prevent myofibroblast transformation in an in vitro model of … MM Ilg, DJ Ralph, S Cellek The Journal of Sexual Medicine 20 (7), 925-934, 2023 | 3 | 2023 |
| Investigating the effect of phosphodiesterase type 5 inhibitors and selective oestrogen receptor modulators in models of Peyronie's disease MM Ilg Anglia Ruskin Research Online (ARRO), 2023 | 1 | 2023 |
| A combination of phosphodiesterase type 5 inhibitor and tamoxifen for acute Peyronie’s disease: the first clinical signals S Cellek, M Megson, MM Ilg, DJ Ralph The Journal of Sexual Medicine 20 (8), 1057-1059, 2023 | 1 | 2023 |
| Investigating the role of extracellular vesicles in peyronie's disease M Ilg, P Dyer, S Bustin, D Ralph, S Cellek The Journal of Sexual Medicine 19 (11), S2-S3, 2022 | 1 | 2022 |
| 277 Interplay between TNFa and TGF-B1 in a cell culture model of Peyronie’s Disease U Milenkovic, MM Ilg, K van Renterghem, D De Ridder, M Albersen The Journal of Sexual Medicine 15 (Supplement_3), S234-S234, 2018 | 1 | 2018 |
| P35 Adaptation of a phenotypic screening assay to incorporate 384-well plates: opening the door to high-throughput screening K Feltham, A Lapthorn, M Ilg, P Dziewulski, S Cellek British Journal of Dermatology 190 (6), e95-e95, 2024 | | 2024 |
| TGF-β1 induces formation of TSG-6-enriched extracellular vesicles in fibroblasts which can prevent myofibroblast transformation by modulating Erk1/2 phosphorylation MM Ilg, SA Bustin, DJ Ralph, S Cellek Scientific Reports 14 (1), 12389, 2024 | | 2024 |
| Temporal gene signature of myofibroblast transformation in Peyronie’s disease: first insights into the molecular mechanisms of irreversibility MM Ilg, S Harding, AR Lapthorn, S Kirvell, DJ Ralph, SA Bustin, G Ball, ... The Journal of Sexual Medicine, qdae006, 2024 | | 2024 |
| Hydroxypyridone anti-fungals selectively induce myofibroblast apoptosis in an in vitro model of hypertrophic scars AR Lapthorn, MM Ilg, P Dziewulski, S Cellek European Journal of Pharmacology, 176369, 2024 | | 2024 |
